CN115252465B - Oil-control, soothing and skin-care composition, cosmetic and preparation method and application thereof - Google Patents
Oil-control, soothing and skin-care composition, cosmetic and preparation method and application thereof Download PDFInfo
- Publication number
- CN115252465B CN115252465B CN202210955687.9A CN202210955687A CN115252465B CN 115252465 B CN115252465 B CN 115252465B CN 202210955687 A CN202210955687 A CN 202210955687A CN 115252465 B CN115252465 B CN 115252465B
- Authority
- CN
- China
- Prior art keywords
- soothing
- oil control
- skin care
- oil
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 244000020551 Helianthus annuus Species 0.000 claims abstract description 40
- 235000015184 Helianthus annuus ssp. lenticularis Nutrition 0.000 claims abstract description 40
- VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 78
- 239000000047 product Substances 0.000 claims description 38
- 235000013399 edible fruits Nutrition 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 15
- 238000007873 sieving Methods 0.000 claims description 14
- 241001254606 Peucedanum praeruptorum Species 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 9
- 238000004821 distillation Methods 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 6
- 239000003974 emollient agent Substances 0.000 claims description 6
- 238000005325 percolation Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000002137 ultrasound extraction Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000003906 humectant Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 56
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 13
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 abstract description 12
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract description 10
- 229960002986 dinoprostone Drugs 0.000 abstract description 10
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract description 10
- 102000004125 Interleukin-1alpha Human genes 0.000 abstract description 9
- 108010082786 Interleukin-1alpha Proteins 0.000 abstract description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 9
- 229940119463 sunflower seed extract Drugs 0.000 abstract description 2
- 102100027456 Cytochrome c oxidase subunit 2 Human genes 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 58
- 235000019198 oils Nutrition 0.000 description 58
- 210000003491 skin Anatomy 0.000 description 57
- 238000012360 testing method Methods 0.000 description 37
- 230000000052 comparative effect Effects 0.000 description 25
- 239000000523 sample Substances 0.000 description 20
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000013642 negative control Substances 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 239000004519 grease Substances 0.000 description 10
- 239000006071 cream Substances 0.000 description 9
- 229960003604 testosterone Drugs 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000002374 sebum Anatomy 0.000 description 7
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 210000003837 chick embryo Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 210000001732 sebaceous gland Anatomy 0.000 description 5
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 229960003473 androstanolone Drugs 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- -1 alkyl glucosides Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 230000009982 effect on human Effects 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 229940012466 egg shell membrane Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 235000005739 manihot Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YEBDWAHEIMUJQT-ZLCLUPBPSA-N (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YEBDWAHEIMUJQT-ZLCLUPBPSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000781993 Erythrina humeana Species 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- LOXVSKUQULMRNO-HVDRVSQOSA-N N[C@@H](CCC(N)=O)C(=O)O.C(CCCCCCCCCCC)(=O)N Chemical compound N[C@@H](CCC(N)=O)C(=O)O.C(CCCCCCCCCCC)(=O)N LOXVSKUQULMRNO-HVDRVSQOSA-N 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940083913 c14-22 alcohols Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- CNRDTAOOANTPCG-UHFFFAOYSA-N dodecyl carbamate Chemical compound CCCCCCCCCCCCOC(N)=O CNRDTAOOANTPCG-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940043707 polyglyceryl-6 distearate Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to the technical field of cosmetics, and provides an oil-control, soothing and skin-care composition, a cosmetic, a preparation method and application thereof. The oil control and skin care composition comprises the following components in parts by weight: 0.1-1.0 part of zinc hyaluronate, 1.0-20 parts of wild sunflower seed extract and 1.0-20 parts of radix peucedani extract. The oil control effect is achieved through the multi-channel effect by inhibiting the activities of 5 alpha-reductase and COX2 factors, and the relief effect is achieved through the activities of IL-1 alpha, TNF-a and PGE2 factors. The oil-control, soothing and skin-care cosmetic solves the problem that the existing oil-control, soothing and skin-care cosmetic is poor in oil-control and soothing effect, and therefore has good practical popularization and application values.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to an oil-control, soothing and skin-care composition, a cosmetic, a preparation method and application thereof.
Background
The disclosure of this background section is only intended to increase the understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art already known to those of ordinary skill in the art.
Sebum is produced by sebaceous gland cells in the skin and then secreted to the skin surface, and a sebum film formed by sebum and sweat on the surface of the human body is one of important components of the first barrier of the human body, and the normal sebum secretion amount is very important for maintaining the health state of the skin. Excessive secretion of skin grease can cause bad appearance and uncomfortable touch feeling of the skin, excessive sebum is distributed on the surface of the skin, dust is easy to stain, normal functions are exerted to a certain extent, and certain degree of trouble is brought to daily life activities for people. Thus, oil control is an important solution to treat such skin problems, and conditioning of oily skin is one of the problems many consumers seek to improve.
Abnormal sebaceous gland secretion is usually caused by hyperandrogens, testosterone and Dihydrotestosterone (DHT) are androgens, and DHT is 5-10 times more active than testosterone. 5α -reductase is a direct catalytic enzyme in the process of converting testosterone into DHT, and expression of DHT affects proliferation and differentiation of sebaceous gland cells, thereby causing excessive secretion of grease from sebaceous glands.
Factors such as environment, UVB, hormone and the like can induce the expression of cyclooxygenase-2 (COX 2), COX2 is a key rate-limiting enzyme in the synthesis process of Prostaglandin (PGs), COX2 catalyzes arachidonic acid (arachidonic acid) to generate PGs, the synthesized PGD2 and an intermediate product are endogenous ligands of peroxide proliferation activating receptor gamma (PPARgamma), and the activation of PPARgamma cooperates with the formation of heterodimers of retinoid receptor (RXR) to initiate the expression of a series of target genes, so that the proliferation of sebaceous cells and the increase of sebum secretion are stimulated.
Excessive secretion of grease can cause pressure increase in the catheter to form a low-oxygen environment, propionibacterium acnes grow in the low-oxygen environment, and the keratinocytes are stimulated to generate pro-inflammatory factors IL-1 alpha, TNF-alpha and inflammatory mediators PGE2, and when the catheter is ruptured, the release can cause strong local reaction of an innate immune system, and various degrees of itching, burning, stinging, erythema and the like are generated.
The inventor finds that although a large number of cosmetics with the oil control and relief effects are promoted in the market at present, the problems of poor oil control and relief effects, complex production and preparation process, high price and the like generally exist.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide an oil-control, soothing and skin-care composition, a cosmetic, a preparation method and application thereof. Proved by experiments, the composition and the cosmetic provided by the invention have strong capability of inhibiting grease secretion and relieving skin, so that the composition and the cosmetic have good practical popularization and application values.
In order to achieve the technical purpose, the technical scheme provided by the invention is as follows:
in a first aspect, the invention provides an oil control and skin care composition, which comprises the following components in parts by weight:
0.1-1.0 part of zinc hyaluronate, 1-20 parts of wild sunflower fruit extract and 1-20 parts of radix peucedani extract.
Wherein the molecular weight of the zinc hyaluronate is controlled to be 40-80 Da, and the preferred molecular weight of the zinc hyaluronate is 50-70 Da.
The wild sunflower fruit extract can be obtained in a commercial mode, and in a specific embodiment of the invention, the wild sunflower fruit extract is prepared by the following method:
s1, crushing and sieving the wild sunflower fruits, and obtaining a wild sunflower fruit percolate by using ethanol as a solvent through a percolation method;
s2, distilling and concentrating the wild sunflower fruit percolate obtained in the step S1, and then adding glycerol into the distilled and concentrated wild sunflower fruit percolate.
The radix peucedani extract can also be obtained in a commercial mode, and in a specific embodiment of the invention, the radix peucedani extract is prepared by the following method:
s1, crushing and sieving peucedanum praeruptorum, soaking the crushed peucedanum praeruptorum in ethanol for ultrasonic extraction, filtering, collecting filtrate, repeatedly extracting filter residues for 2-3 times, and combining the obtained filtrate;
s2, concentrating the filtrate obtained in the step S1 under reduced pressure, recovering ethanol until no ethanol smell exists, adding butanediol, stirring uniformly, and filtering to obtain the product.
In a second aspect of the invention, there is provided the use of the above composition for the preparation of a cosmetic for controlling oil, soothing skin. Experiments prove that the composition can inhibit COX2 activity by inhibiting 5 alpha-reductase activity, thereby achieving the effects of effectively inhibiting grease secretion and controlling oil; simultaneously, the activity of IL-1 alpha, TNF-alpha and PGE2 inflammatory factors can be inhibited externally, so that an excellent relieving effect is achieved; meanwhile, the cosmetic is safe and has no toxic or side effect, so that the cosmetic can be applied to cosmetics for controlling oil, relieving and protecting skin.
Accordingly, in a third aspect of the present invention, there is provided an oil-controlling, soothing and skin-protecting cosmetic comprising the above composition.
The oil control soothing skin care cosmetic may also contain any other ingredients that the cosmetic art allows to add, including but not limited to emulsifiers, emollients, moisturizers, thickeners, and the like.
Meanwhile, different cosmetic formulations such as essence water, essence cream and essence cream can be prepared by reasonably adding the raw material components, and meanwhile, the obtained cosmetic products are further derived and prepared based on the basic cosmetic products, which obviously belong to the protection scope of the application.
In a fourth aspect of the present invention, there is provided a method for preparing the oil-controlling, soothing and skin-care cosmetic described above, comprising the step of mixing a composition comprising the composition described in the first aspect above with other raw material components.
In a fifth aspect of the invention there is provided the use of the above composition and/or cosmetic in oil control, soothing and skin care.
The beneficial technical effects of one or more of the technical schemes are as follows:
the oil control and relieving skin care cosmetic obtained by the technical scheme has excellent oil control capability and relieving capability effect; the activity of COX2 is inhibited by inhibiting the activity of 5 alpha-reductase in vitro, so that the effects of effectively inhibiting the secretion of grease and controlling the oil are achieved; the excellent relieving effect is achieved by inhibiting the activities of IL-1 alpha, TNF-alpha and PGE2 inflammatory factors in vitro; further, through the experimental test of human body efficacy, the cosmetic has good oil control and relieving functions and obvious efficacy.
Meanwhile, the preparation method of the oil-control skin-care cosmetics with relief effect is simple and easy to implement, raw materials are easy to obtain, and the oil-control skin-care cosmetics are suitable for mass production, so that the oil-control skin-care cosmetics have good practical application value.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for the description of the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only embodiments of the present invention, and that other drawings may be obtained according to the provided drawings without inventive effort for a person skilled in the art.
Fig. 1: the effect of different test samples on 5α -reductase activity (# # indicates p <0.01 compared to the blank control; x indicates p <0.01 compared to the negative control)
Fig. 2: bar graph of lipid drop synthetic oil red O staining results for test samples (# # indicates p <0.01 compared to blank control;: < p <0.01 compared to negative control
Fig. 3: skin lipid content measurement after application of the product (P < 0.001)
Fig. 4: comparison of skin lipid content changes after application of the product (P < 0.001)
Fig. 5: skin relief change after application of the product.
Detailed Description
It should be noted that the following detailed description is illustrative and is intended to provide further explanation of the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments in accordance with the present application. As used herein, the singular is also intended to include the plural unless the context clearly indicates otherwise, and furthermore, it is to be understood that the terms "comprises" and/or "comprising" when used in this specification are taken to specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof.
In one exemplary embodiment of the invention, an oil control and soothing skin care composition is provided, which comprises the following components in parts by weight:
0.1-1.0 part of zinc hyaluronate, 1-20 parts of wild sunflower fruit extract and 1-20 parts of radix peucedani extract.
Experiments prove that the combination of the zinc hyaluronate, the wild sunflower seed extract and the radix peucedani extract has good oil control and relief effects, and can be used for improving oily skin problems in cosmetics.
Wherein the molecular weight of the zinc hyaluronate is controlled to be 40-80 Da, and the preferred molecular weight of the zinc hyaluronate is 50-70 Da.
The wild sunflower fruit extract can be obtained in a commercial mode, and in a specific embodiment of the invention, the wild sunflower fruit extract is prepared by the following method:
s1, crushing and sieving the wild sunflower fruits, and obtaining a wild sunflower fruit percolate by using ethanol as a solvent through a percolation method;
s2, distilling and concentrating the wild sunflower fruit percolate obtained in the step S1, and then adding glycerol into the distilled and concentrated wild sunflower fruit percolate.
Wherein,,
in the step S1, a 60-100 mesh sieve, such as 60, 70, 80, 90 or 100 mesh sieve is selected for sieving treatment; in one embodiment of the invention, the sieving treatment is an 80 mesh sieve.
The specific method for obtaining the wild sunflower fruit percolate by using ethanol as a solvent by adopting a percolation method comprises the following steps:
placing the crushed and sieved wild sunflower seed powder into a percolating cylinder, adding 30% -70% (preferably 50%) ethanol with the amount of 3-8 times (preferably 5 times) of the wild sunflower seed powder, soaking for 6-12 h, collecting 10-20 times (preferably 15 times) of the percolate of the wild sunflower seed powder at the flow rate of 7-10mL/min, and filtering to obtain filtrate.
In the step S2, distillation and concentration are specifically carried out by adopting reduced pressure distillation treatment at 55-65 ℃, when the residual amount of the filtrate is 1/6-1/3 (preferably 1/5) of the original filtrate, glycerol with the amount of 1-1.5 times of the residual concentrated solution is added, and the mixture is stirred uniformly and filtered to obtain the product.
The radix peucedani extract can also be obtained in a commercial mode, and in a specific embodiment of the invention, the radix peucedani extract is prepared by the following method:
s1, crushing and sieving peucedanum praeruptorum, soaking the crushed peucedanum praeruptorum in ethanol for ultrasonic extraction, filtering, collecting filtrate, repeatedly extracting filter residues for 2-3 times, and combining the obtained filtrate;
s2, concentrating the filtrate obtained in the step S1 under reduced pressure, recovering ethanol until no ethanol smell exists, adding butanediol, stirring uniformly, and filtering to obtain the product.
Wherein,,
in the step S1, a 30-60 mesh sieve, such as 30, 40, 50 or 60 mesh sieve is selected for sieving treatment; in one embodiment of the invention, a 50 mesh screen is selected for the screening process.
The ethanol is 60-85% ethanol, the feed liquid ratio (w/w) is 1:8-1:10, and the ethanol is soaked for 10-30min (preferably 20 min); the ultrasonic power is 100-300W (preferably 200W) in the ultrasonic extraction process, and the ultrasonic treatment time is 30-40min;
in the step S2, the reduced pressure concentration is specifically carried out by carrying out reduced pressure distillation treatment at 50-60 ℃, recovering ethanol until no alcohol smell exists to obtain a peucedanum praeruptorum concentrated solution, adding butanediol with the mass of 2-2.5 times of that of the peucedanum praeruptorum concentrated solution, stirring uniformly, and filtering to obtain the finished product.
In another specific embodiment of the invention, the oil control and skin relief composition comprises the following components in parts by weight:
0.3 part of zinc hyaluronate, 10 parts of wild sunflower fruit extract and 10 parts of radix peucedani extract.
In a second aspect of the invention, there is provided the use of the above composition for the preparation of a cosmetic for controlling oil, soothing skin. Experiments prove that the composition can inhibit COX2 activity by inhibiting 5 alpha-reductase activity, thereby achieving the effects of effectively inhibiting grease secretion and controlling oil; simultaneously, the activity of IL-1 alpha, TNF-alpha and PGE2 inflammatory factors can be inhibited externally, so that an excellent relieving effect is achieved; meanwhile, the cosmetic is safe and has no toxic or side effect, so that the cosmetic can be applied to cosmetics for controlling oil, relieving and protecting skin.
Accordingly, in yet another embodiment of the present invention, there is provided an oil-controlling, soothing and skin-protecting cosmetic comprising the above composition.
The oil-controlling and skin-soothing cosmetic according to the present invention is added in an amount of 0.5 to 40%, preferably 2 to 25%, such as 2%, 5%, 10%, 15%, 20%, 25%, 30% or 40% based on the total mass of the oil-controlling and skin-soothing cosmetic.
The oil control soothing skin care cosmetic may also contain any other ingredients that the cosmetic art allows to add, including but not limited to emulsifiers, emollients, moisturizers, thickeners, and the like.
In a further embodiment of the present invention, the emulsifier is added in an amount of 1 to 6%, preferably in an amount of 2 to 5% based on the total mass of the oil control soothing skin care cosmetic; the addition amount of the emollient is 6-25%, and the preferable addition amount is 8-20%; the addition amount of the humectant is 2-15%, and the preferable addition amount is 5-12%; the thickener is added in an amount of 0.02-1.0%, preferably 0.05-0.8%.
In yet another embodiment of the present invention, the oil control and soothing skin care cosmetic according to the present invention, the emulsifier comprises any one or a combination of two or more of polyglyceryl-6 stearate, polyglyceryl-6 behenate, polyglyceryl-6 distearate, polyglyceryl-3 bee wax esters, C14-22 alcohols, C12-20 alkyl glucosides, cetostearyl olivate, sorbitan olivate, hydrogenated lecithin, inulin lauryl carbamate, sodium bis (lauramide glutamine) lysine, sodium surfactin.
In yet another embodiment of the present invention, the oil control relief skin care cosmetic according to the present invention comprises any one or a combination of two or more of isononyl isononanoate, squalane, caprylic/capric triglyceride, monkey-tree seed oil, berhard walnut seed oil, white pool seed oil, polydimethylsiloxane, cyclopentadimethicone, isododecane, tri (ethylhexanoic) glyceride, behenyl alcohol, shea butter, dioctyl carbonate, tocopheryl acetate.
In still another embodiment of the present invention, the oil-controlling and soothing skin care cosmetic according to the present invention, the moisturizer comprises any one or a combination of two or more of glycerin, butylene glycol, 1, 2-hexanediol, ethylhexyl glycerin, sodium hyaluronate, panthenol, and trehalose.
In yet another embodiment of the present invention, the oil control and soothing skin care cosmetic according to the present invention, the thickener comprises any one or a combination of two or more of sodium polyacrylate, carbomer, xanthan gum, hydroxyethyl cellulose, ammonium acryloyldimethyl taurate/VP copolymer, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, polyacrylate crosslinked polymer-6.
Meanwhile, different cosmetic formulations such as essence water, essence cream and essence cream can be prepared by reasonably adding the raw material components, and meanwhile, the obtained cosmetic products are further derived and prepared based on the basic cosmetic products, which obviously belong to the protection scope of the application.
In still another embodiment of the present invention, there is provided a method for preparing the oil-controlling and soothing skin-care cosmetic described above, comprising the step of mixing the composition comprising the above first aspect with other raw material components.
In yet another embodiment of the present invention, there is provided the use of the above composition and/or cosmetic for oil control, soothing and skin care.
The invention is further illustrated below with reference to examples. The invention is further illustrated by means of the following examples, which are not intended to limit the invention thereto. Based on the embodiments of the present invention, any changes to the present invention without making any creative changes to the present invention fall within the protection scope of the present invention. Meanwhile, in the examples of the present invention, all the preparation materials are commercially available products well known to those skilled in the art unless otherwise specified.
Examples
An oil-controlling and skin-caring composition comprises zinc hyaluronate, herba Abelmoschi Manihot fruit extract and radix Peucedani extract.
Wherein the molecular weight of the zinc hyaluronate is 50 ten thousand Da.
The obtaining method of the wild sunflower fruit extract comprises the following steps:
(1) Pulverizing dry fructus Mali Pumilae, sieving with 80 mesh sieve, placing fructus Mali Pumilae powder in a percolating cylinder, adding 5 times of 50% ethanol, soaking for 10 hr, collecting 15 times of percolate extract of fructus Mali Pumilae powder at 8mL/min, and filtering.
(2) Placing the wild sunflower fruit percolate obtained in the step (1) in a rotary evaporator, vacuumizing, distilling under reduced pressure at 60 ℃, adding glycerol with the mass 1.5 times of that of the concentrated solution when the filtrate is evaporated to one fifth, stirring uniformly, and filtering to obtain the wild sunflower fruit extract.
The method for obtaining the extract of the peucedanum praeruptorum dunn comprises the following steps:
(1) Pulverizing dried radix Peucedani, sieving with 50 mesh sieve, pulverizing radix Peucedani Hu Jinpao, soaking in 70% ethanol at a mass ratio of 1:9 for 20min, extracting under ultrasonic power of 200W for 30min, filtering, collecting filtrate, repeatedly extracting the residue twice, and mixing the three filtrates.
(2) Placing the filtrate obtained in the step (1) in a rotary evaporator, vacuumizing, distilling under reduced pressure at 60 ℃, recovering ethanol until no alcohol smell exists, adding 2.5 times of butanediol in the radix peucedani concentrate, stirring uniformly, and filtering to obtain the radix peucedani extract.
Examples 1-3 and comparative examples 1-4 preparation methods: mixing zinc hyaluronate, herba Abelmoschi Manihot extract and radix Peucedani extract, and dissolving in purified water. The specific scheme is shown in the following table 1, calculated as mass ratio.
Table 1 list of specific examples and comparative examples
Example 4 essence Water
The formula of the essence aquatic product containing the oil-controlling and soothing skin-care composition is shown in table 2.
Table 2 essential aquatic product formulation
The preparation method of the essence water comprises the following steps:
s1: respectively adding the raw materials in the phase A, heating to 85 ℃ and stirring for dissolution;
s2: after the dissolution is completed, cooling is started, the components in the phase B are respectively added when the temperature is reduced to 45 ℃, and stirring, dissolution and uniform dispersion are carried out;
s3: when the temperature is reduced to 40 ℃, the C phase component is added in sequence, and the essence aquatic product is obtained after stirring, dissolving and dispersing uniformly.
Comparative example 5 was prepared as in example 4 except that comparative example 5 did not contain an oil control skin soothing and care composition and the amount of oil control skin soothing and care composition in example 4 was made up by adding water.
Example 5 essence emulsion
The oil control and skin care composition is applied to prepare an essence milk product containing the oil control and skin care composition, and the formula is shown in table 3.
Table 3 essential milk product formulation
The preparation method of the essence emulsion comprises the following steps:
s1: preparation of an aqueous phase: respectively adding the raw materials in the phase A, heating to 85 ℃ and stirring for dissolution;
s2: preparation of an oil phase: respectively adding the raw materials in the phase B, heating to 80 ℃ and melting;
s3: mixing phase A and phase B, homogenizing (3000 rpm) for 12min;
s4: after homogenization, adding phase C, stirring uniformly, and starting to cool;
s5: adding phase D when the temperature is reduced to 70 ℃, stirring and dissolving, and continuing to reduce the temperature after dissolving;
s6: and when the temperature is reduced to 45 ℃, sequentially adding the E phase component, stirring, dissolving and dispersing uniformly to obtain the essence milk product.
Example 6 essence cream
The oil control and skin care composition is applied to prepare an essence cream product containing the oil control and skin care composition, and the formula is shown in table 4.
Table 4 essential cream product formulation
The preparation method of the essence cream comprises the following steps:
s1: preparation of an aqueous phase: respectively adding the raw materials in the phase A, heating to 85 ℃ and stirring for dissolution;
s2: preparation of an oil phase: respectively adding the raw materials in the phase B, heating to 80 ℃ and melting;
s3: mixing phase A and phase B, homogenizing (3000 r/min), homogenizing for 12min;
s4: after homogenization, cooling is started, when the temperature is reduced to 70 ℃, adding the phase C, stirring and dissolving, and cooling is continued after the dissolution is completed;
s5: and when the temperature is reduced to 45 ℃, adding the phase D components in sequence, stirring, dissolving and dispersing uniformly to obtain the essence cream product.
Test example 1: safety test experiment
The product was subjected to eye irritation test, i.e., safety test, with reference to SN/T2329-2009 "cosmetic eye irritation/chick embryo chorioallantoic membrane test".
The experimental method comprises the following steps: fertilized chick embryos within 7 days of age are adopted to be incubated for 9 days in an incubator with humidity of 50% -70% at 37.6+/-0.5 ℃.
CAM preparation: egg candling is performed by marking the air chamber locations on the eggshell surface, and the labeled eggshell portions are peeled off with tweezers to expose the white eggshell membrane, taking care not to disrupt the integrity of the eggshell membrane. 0.5mL of 0.9% NaCl solution is added dropwise to fully wet the egg membrane, surface liquid is gently sucked by a paper towel, and the inner membrane is carefully removed by forceps, so that the vascular membrane is not damaged.
Reaction end point method: and uniformly dripping or smearing 0.3mL of transparent test object on the surface of the CAM, washing the test object by using 0.9% NaCl solution after 3min of action, and observing the degree of each toxicity effect change of the CAM.
Endpoint scoring method (end point score ES): the end point score (ES) should be calculated for the test performed using the reaction end point method, with the result remaining two decimal places. Score per chick embryo = sum of extent of bleeding, clotting and vascular thawing observed per chick embryo, ES = mathematical sum of 6 chick embryo scores. The eye irritation of the test subjects was classified according to the ES values as shown in table 5.
TABLE 5 determination criteria for end-of-reaction results
| Stimulation scoring | ES≤12 | 12<ES<16 | ES≥16 |
| Irritation classification | No/light irritation | Moderate irritation | Strong irritation/corrosiveness |
The test results are shown in Table 6. The oil control, soothing and skin care compositions are non-irritating.
TABLE 6 statistical tables of results of irritation experiments
Test example 2: in vitro assay for inhibiting 5 alpha-reductase Activity
Testosterone is converted to Dihydrotestosterone (DHT) by 5α -reductase in the presence of NADPH, and DHT expression affects sebaceous cell proliferation and differentiation. Therefore, the inhibition effect of the object to be detected on the 5 alpha-reductase can be evaluated by measuring the content change of the substrate testosterone in the 5 alpha-reductase active reaction system by adopting an ultra-high performance liquid tandem mass spectrometry (UPLC-MS).
The inhibition rate is calculated according to the formula: i (%) = [ (B-Q) - (B-R) ]/(B-Q) ×100.B represents testosterone content of a blank control group, Q represents testosterone content of a reaction group without inhibitor, and R represents testosterone content of a reaction group with inhibitor to be tested.
The original concentration of each component in the enzyme reaction system is respectively as follows: buffer solution [ Tris-HCl, pH 7.4]; NADPH concentration (10 mmol/L, sigma 93205); 5 alpha-reductase concentration is 10mg/mL; testosterone 4 μg/mL; dutasteride concentrations were 0.5mg/mL.
Table 7 liquid adding table for reaction system
And/represents without addition of corresponding substances
The test results are shown in FIG. 1, and each of example 1, example 2, example 3, comparative example 1, comparative example 2, comparative example 3 and comparative example 4 has a significant in vitro inhibition of 5α -reductase activity, with an inhibition rate of 69.44% for example 1, 87.75% for example 2, 78.03% for example 3, 44.16% for comparative example 1, 52.50% for comparative example 2, 54.68% for comparative example 3 and 5.22% for comparative example 4. The most obvious inhibition effect of the embodiment 2 shows that the oil control, relieving and skin care composition has obvious function of inhibiting 5 alpha-reductase activity, thereby achieving the oil control effect.
Test example 3: in vitro Activity assay for inhibiting IL-1 alpha, TNF-alpha, COX2 and PGE2 factors
The ability of the test substance to inhibit the expression of the relevant cell pathway factors was evaluated by inducing mouse macrophages Raw264.7 with LPS (bacterial lipopolysaccharide) and detecting the expression levels of IL-1α, TNF- α, COX2 and PGE2 by ELISA. See table 8 for test protocols.
Table 8 test protocol
The test results are shown in tables 9-12.
TABLE 9 summary of IL-1 alpha content results
( And (3) injection: # represents p <0.01 compared to the blank; * Represents p <0.01 compared to negative control; * Represents 0.01< p <0.05 compared to the negative control. )
As can be seen from Table 9, examples 1,2,3 and comparative examples 1,2,3,4 each significantly inhibited IL-1α activity, and example 2 showed the most significant inhibition, but comparative examples 1,2,3,4 each had a lower inhibition than examples 1,2,3, and in particular comparative example 1 was much lower than example 2. The oil-control, soothing and skin-care composition can obviously inhibit the activity of IL-1 alpha.
TABLE 10 summary of TNF-alpha content results
( And (3) injection: # represents p <0.01 compared to the blank; * Represents p <0.01 compared to negative control; * Represents 0.01< p <0.05 compared to the negative control. )
As can be seen from Table 10, examples 1,2,3 and comparative examples 1,2,3,4 each significantly inhibited TNF-. Alpha.activity, but comparative examples 1,2,3,4 each inhibited less than examples 1,2,3, and particularly comparative example 1 was much lower than each example. The oil-control, soothing and skin-care composition can obviously inhibit the activity of TNF-alpha.
TABLE 11 summary of PGE2 content results
( And (3) injection: # represents p <0.01 compared to the blank; * Represents p <0.01 compared to negative control; * Represents 0.01< p <0.05 compared to the negative control. )
As can be seen from Table 11, examples 1,2,3 and comparative examples 1,2,3,4 each significantly inhibited PGE2 activity, and example 2 showed the most significant inhibition, but comparative examples 1,2,3,4 each had a lower inhibition than examples 1,2,3, and particularly comparative example 1 was much lower than each example. The oil control, soothing and skin care composition is shown to significantly inhibit the activity of PGE 2.
TABLE 12 summary of COX2 content results
( And (3) injection: # represents p <0.01 compared to the blank; * Represents p <0.01 compared to negative control; * Represents 0.01< p <0.05 compared to the negative control. )
As can be seen from Table 12, examples 1,2,3 and comparative examples 1,2 and 3 each significantly inhibited COX2 activity, with example 2 having the most significant inhibition, but comparative example 4 having no significant inhibition, and comparative examples 1,2 and 3 being much lower than each example. The oil-control, soothing and skin-care composition is shown to significantly inhibit COX2 activity.
From the results, the oil control, relief and skin care composition can obviously inhibit the activities of IL-1 alpha, TNF-alpha, COX2 and PGE2 factors and has a certain oil control, relief and skin care effect.
Test example 4: in vitro oil control experiment of example 4
The test evaluates the oil control efficacy of the test article by detecting the lipid drop content of the sample on sebaceous gland cell SZ 95.
According to the test scheme of Table 13, when the cell plating rate in the 24-well plate reaches 40% -50%, group administration is carried out, 1mL of sample is added to each well, and 3 compound wells are arranged in each group. After completion of the administration, the 24-well plate was placed in an incubator (37 ℃, 5% co 2) and cultured for 24 hours.
Oil red O staining: the old solution was aspirated, the cells were washed 1 time with PBS, 500. Mu.L of oil red O working solution (1. Mu.g/mL) was added to each well, stained in the dark for 15min (incubation at 37 ℃ C.) and washed 2 times with PBS.
The oil control ability was evaluated based on the OD value of the fat drop synthetic oil red O staining results. Lower OD values indicate less secreted oil content and greater oil control.
Inhibition ratio calculation formula = (NC group OD value-sample OD value)/NC group OD value 100%
Table 13 test plan design
The test results are shown in fig. 2, the OD value of example 4 is significantly lower than that of the negative control group (NC group), the inhibition rate is 12.63%, and the oil control effect is significant, so that the oil control soothing skin care composition product has a certain oil control capability.
Test example 5: example 4 Effect in controlling oil on human skin
The oil control effect on human skin was evaluated on the basis of the essential water product of example 4.
The method refers to: T/ZHCA 002-2018, cosmetic oil control efficacy test method.
30 healthy female/male volunteers aged 18-50 years old were selected, whose skin oil content Sebum was not less than 120 (. Mu.g/cm) 2 )。
Test item
Where T0 means that the subject is not using the sample, T2 means that the subject is using the sample for 2 hours once, T4 means that the subject is using the sample for 4 hours once, and T8 means that the subject is using the sample for 8 hours once.
Comparative example 5 was selected for the experimental blank.
The detection method comprises the following steps:
1) The sample areas and the blank areas are randomly distributed on the left and right sides of the forehead, so that the positions of all the sample areas and the blank areas are ensured to reach equilibrium statistically;
2) 0.5g of test sample is smeared on a measurement area, cleaning is not needed, and a control sample is smeared in a blank area;
3) The measurement of the sample area and the blank area was performed in a skin grease meter, and each area was measured in parallel 3 times. Measuring initial values of all test areas (before using samples), and then measuring skin grease contents of a sample area and a blank area after using the samples for 2 hours, 4 hours and 8 hours;
4) Testing of the same subject must be accomplished by the same measurement personnel using the same instrument;
the test should be terminated immediately during the use of the sample as the skin of the volunteer develops an adverse reaction, and the volunteer is appropriately treated and the adverse reaction is recorded.
The grease inhibition rate calculation formula: (blank area increment-sample area increment)/blank area increment 100%
Test results:
the test results are shown in fig. 3 and 4, and the skin oil increment of the sample is significantly improved compared with the blank area of the control sample after 2 hours, 4 hours and 8 hours of single use of the sample. The inhibition rate after two hours of using the sample is 21.46%, the inhibition rate after 4 hours of using the sample is 22.55%, the inhibition rate after 8 hours of using the sample is 18.42%,
the results show that: the essential oil product of example 4 was able to improve skin oil secretion and had an oil control effect for 8 hours, indicating that the essential oil product containing the oil control soothing skin care composition had a remarkable oil control effect.
Test example 6: example 4 soothing Effect on human skin
Example 4 essence water product prepared was tested for human skin efficacy and product testing was conducted on 30 volunteers 18-40 years old (skin condition: skin sensitivity (lactic acid stinging positive)).
Detection time: trial product for 14 days, 28 days;
detection equipment: VISIA skin Detector (CanField Co., USA).
The test collects pictures of the face of a subject under the left, middle and right three standard light 1, standard light 2 and 3 light sources of cross polarized light and derives red region pictures under the cross polarized light. And carrying out image analysis on the red region picture to obtain a quantitative index red region analysis a, wherein the quantitative index red region analysis a is used for evaluating improvement conditions of redness and sensitivity states of facial skin.
Test results:
pictures of red area changes in front and rear faces of the samples were used for 2 subjects as exemplified in fig. 5.
Table 14-1 red area analysis a descriptive statistics (n=30) of values
Table 14-2 red area analysis a statistical analysis results (n=30)
Statistical analysis results: "-": the difference has no statistical significance (P is more than or equal to 0.05); "*": the difference is statistically significant (P is more than or equal to 0.01 and less than or equal to 0.05); "**": the difference is statistically significant (P < 0.001); "***": the differences were statistically significant (P < 0.001).
Red area analysis a value test results show that compared with the test sample before use, the red area analysis a value is obviously reduced (0.01 less than or equal to P < 0.05) after 4 weeks of use, and the product containing the oil control and skin care composition has a soothing effect.
The results show that: the product containing the oil-control skin-soothing composition can achieve the effect of controlling oil and soothing skin, and has remarkable effect when being used in skin care products.
It should be noted that the above examples are only for illustrating the technical solution of the present invention and are not limiting thereof. Although the present invention has been described in detail with reference to the examples given, those skilled in the art can make modifications and equivalents to the technical solutions of the present invention as required, without departing from the spirit and scope of the technical solutions of the present invention.
Claims (18)
1. An oil control and skin care composition is characterized by comprising the following components in parts by mass:
0.1-1.0 part of zinc hyaluronate, 1-20 parts of wild sunflower fruit extract and 1-20 parts of radix peucedani extract;
the molecular weight of the zinc hyaluronate is controlled to be 40-80 Da;
the wild sunflower fruit extract is prepared by the following method:
s1, crushing and sieving the wild sunflower fruits, and obtaining a wild sunflower fruit percolate by using ethanol as a solvent through a percolation method;
s2, distilling and concentrating the wild sunflower fruit percolate obtained in the step S1, and then adding glycerol into the distilled and concentrated wild sunflower fruit percolate to obtain the wild sunflower fruit beverage;
in the step S1, a 60-100 mesh sieve is selected in the sieving treatment;
the specific method for obtaining the wild sunflower fruit percolate by using ethanol as a solvent by adopting a percolation method comprises the following steps:
placing the crushed and sieved wild sunflower seed powder into a percolating cylinder, adding 30% -70% ethanol with the amount of 3-8 times of the wild sunflower seed powder, soaking for 6-12 hours, collecting percolate with the amount of 10-20 times of the wild sunflower seed powder at the flow rate of 7-10mL/min, and filtering to obtain filtrate;
in the step S2, distillation and concentration are specifically carried out by adopting reduced pressure distillation treatment at 55-65 ℃, and when the filtrate is evaporated to 1/6-1/3 of the original filtrate, glycerol with 1-1.5 times of the residual concentrated solution is added, and the mixture is stirred uniformly and filtered to obtain the product;
the radix peucedani extract is prepared by the following method:
s1, crushing and sieving peucedanum praeruptorum, soaking the crushed peucedanum praeruptorum in ethanol for ultrasonic extraction, filtering, collecting filtrate, repeatedly extracting filter residues for 2-3 times, and combining the obtained filtrate;
s2, concentrating the filtrate obtained in the step S1 under reduced pressure, recovering ethanol until no ethanol smell exists, adding butanediol, uniformly stirring, and filtering to obtain the product;
in the step S1, a sieve with 30-60 meshes is selected for sieving treatment;
the ethanol is 60% -85% ethanol, the feed-liquid ratio is 1:8-1:10, and the mixture is soaked for 10-30min; the ultrasonic power is 100-300W in the ultrasonic extraction process, and the ultrasonic treatment time is 30-40min;
in the step S2, the reduced pressure concentration is specifically carried out by carrying out reduced pressure distillation treatment at 50-60 ℃, recovering ethanol until no alcohol smell exists to obtain a peucedanum praeruptorum concentrated solution, adding butanediol with the mass of 2-2.5 times of that of the peucedanum praeruptorum concentrated solution, stirring uniformly, and filtering to obtain the finished product.
2. The oil control, soothing and skin care composition of claim 1, wherein the zinc hyaluronate has a molecular weight of 50 to 70 kiloda.
3. The oil control, soothing and skin care composition according to claim 1, wherein the preparation method of the wild sunflower fruit extract comprises the step of screening the wild sunflower fruit extract by a 80-mesh screen;
the specific method for obtaining the wild sunflower fruit percolate by using ethanol as a solvent by adopting a percolation method comprises the following steps:
placing the crushed and sieved wild sunflower seed powder into a percolating cylinder, adding 5 times of 50% ethanol, soaking for 6-12 h, collecting 15 times of percolate of the wild sunflower seed powder at a flow rate of 7-10mL/min, and filtering to obtain filtrate;
in the step S2, distillation and concentration are specifically carried out by adopting reduced pressure distillation treatment at 55-65 ℃, and when the filtrate is evaporated to the residual amount of 1/5 of the original filtrate, glycerol with the amount of 1-1.5 times of the residual concentrated solution is added, and the mixture is stirred uniformly and filtered to obtain the product.
4. The oil control, soothing and skin care composition according to claim 1, wherein the step S1 of sieving is carried out by a 50 mesh sieve; the soaking time of the ethanol is 20min; the ultrasonic power in the ultrasonic extraction process is 200W.
5. Use of a composition according to any one of claims 1 to 4 for the preparation of a cosmetic product for controlling oil, soothing skin.
6. A cosmetic product for controlling oil, soothing skin, characterized in that it comprises a composition according to any one of claims 1 to 4.
7. The oil control, soothing and skin care cosmetic according to claim 6, wherein the oil control, soothing and skin care composition is added in an amount of 0.5 to 40% based on the total mass of the oil control, soothing and skin care cosmetic.
8. The oil control, soothing and skin care cosmetic according to claim 7, wherein the oil control, soothing and skin care composition is added in an amount of 2 to 25% based on the total mass of the oil control, soothing and skin care cosmetic.
9. The oil control, soothing and skin care cosmetic according to claim 6, further comprising an emulsifier, an emollient, a humectant and a thickener.
10. The oil control, soothing and skin care cosmetic according to claim 9, wherein the emulsifier is added in an amount of 1 to 6% based on the total mass of the oil control, soothing and skin care cosmetic.
11. The oil control, soothing and skin care cosmetic according to claim 10, wherein the emulsifier is added in an amount of 2 to 5% based on the total mass of the oil control, soothing and skin care cosmetic.
12. The oil control, soothing and skin care cosmetic according to claim 9, wherein the emollient is added in an amount of 6 to 25% based on the total mass of the oil control, soothing and skin care cosmetic.
13. The oil control, soothing and skin care cosmetic according to claim 12, wherein the emollient is added in an amount of 8 to 20% based on the total mass of the oil control, soothing and skin care cosmetic.
14. The oil control, soothing and skin care cosmetic according to claim 9, wherein the humectant is added in an amount of 2 to 15% based on the total mass of the oil control, soothing and skin care cosmetic.
15. The oil control, soothing and skin care cosmetic according to claim 14, wherein the humectant is added in an amount of 5 to 12% based on the total mass of the oil control, soothing and skin care cosmetic.
16. The oil control, soothing and skin care cosmetic according to claim 9, wherein the thickener is added in an amount of 0.02 to 1.0% based on the total mass of the oil control, soothing and skin care cosmetic.
17. The oil control, soothing and skin care cosmetic according to claim 16, wherein the thickener is added in an amount of 0.05 to 0.8% based on the total mass of the oil control, soothing and skin care cosmetic.
18. A method for preparing the oil-controlling, soothing and skin-protecting cosmetic according to any one of claims 6 to 17, characterized in that it comprises the step of mixing the raw material components.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210955687.9A CN115252465B (en) | 2022-08-10 | 2022-08-10 | Oil-control, soothing and skin-care composition, cosmetic and preparation method and application thereof |
| PCT/CN2023/110819 WO2024032447A1 (en) | 2022-08-10 | 2023-08-02 | Oil-control soothing skin-care composition and cosmetic, preparation method therefor, and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210955687.9A CN115252465B (en) | 2022-08-10 | 2022-08-10 | Oil-control, soothing and skin-care composition, cosmetic and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115252465A CN115252465A (en) | 2022-11-01 |
| CN115252465B true CN115252465B (en) | 2023-07-28 |
Family
ID=83751192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210955687.9A Active CN115252465B (en) | 2022-08-10 | 2022-08-10 | Oil-control, soothing and skin-care composition, cosmetic and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115252465B (en) |
| WO (1) | WO2024032447A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252465B (en) * | 2022-08-10 | 2023-07-28 | 山东福瑞达生物股份有限公司 | Oil-control, soothing and skin-care composition, cosmetic and preparation method and application thereof |
| CN115944548B (en) * | 2023-02-03 | 2024-06-21 | 山东福瑞达生物股份有限公司 | Oil control composition for improving light stability of ergothioneine and application thereof |
| CN117205127A (en) * | 2023-10-27 | 2023-12-12 | 暨南大学 | Extraction method and application of Hu Huoxing components in white flower |
| CN117860634B (en) * | 2024-02-20 | 2024-06-25 | 广州协携生物科技有限公司 | Skin-care composition for relieving and preparation method and application thereof |
| CN118141700B (en) * | 2024-03-01 | 2024-09-10 | 广州青囊生物科技有限公司 | Oil-control anti-inflammatory composition and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108078833A (en) * | 2017-12-11 | 2018-05-29 | 中山中研化妆品有限公司 | A kind of weight reducing fat reducing frost and preparation method thereof |
| CN108403524A (en) * | 2018-05-12 | 2018-08-17 | 佛山云裳化妆品有限公司 | A kind of efficient spot-eliminating composition and its application |
| CN110167527A (en) * | 2016-12-29 | 2019-08-23 | 巴斯夫美容护理法国公司 | Purposes of the coconut water as Extraction solvent |
| KR102004322B1 (en) * | 2018-12-03 | 2019-10-01 | 주식회사 웰코스 | Cosmetic composition containing botanical extract complex |
| CN114569491A (en) * | 2022-04-18 | 2022-06-03 | 华熙生物科技股份有限公司 | Composition for inhibiting generation of oil and fat and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553352A (en) * | 2018-04-29 | 2018-09-21 | 佛山云裳化妆品有限公司 | One kind going red blood silk composition and its application |
| KR102213767B1 (en) * | 2018-12-12 | 2021-02-09 | 주식회사 코리아나화장품 | Cosmetic Composition For Preventing Hair Loss Containing Malva verticillata L. Seed Extract |
| CN115252465B (en) * | 2022-08-10 | 2023-07-28 | 山东福瑞达生物股份有限公司 | Oil-control, soothing and skin-care composition, cosmetic and preparation method and application thereof |
-
2022
- 2022-08-10 CN CN202210955687.9A patent/CN115252465B/en active Active
-
2023
- 2023-08-02 WO PCT/CN2023/110819 patent/WO2024032447A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110167527A (en) * | 2016-12-29 | 2019-08-23 | 巴斯夫美容护理法国公司 | Purposes of the coconut water as Extraction solvent |
| CN108078833A (en) * | 2017-12-11 | 2018-05-29 | 中山中研化妆品有限公司 | A kind of weight reducing fat reducing frost and preparation method thereof |
| CN108403524A (en) * | 2018-05-12 | 2018-08-17 | 佛山云裳化妆品有限公司 | A kind of efficient spot-eliminating composition and its application |
| KR102004322B1 (en) * | 2018-12-03 | 2019-10-01 | 주식회사 웰코스 | Cosmetic composition containing botanical extract complex |
| CN114569491A (en) * | 2022-04-18 | 2022-06-03 | 华熙生物科技股份有限公司 | Composition for inhibiting generation of oil and fat and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024032447A1 (en) | 2024-02-15 |
| CN115252465A (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115252465B (en) | Oil-control, soothing and skin-care composition, cosmetic and preparation method and application thereof | |
| KR102057022B1 (en) | Cosmetic composition and manufacturing method for the same | |
| JP2021020886A (en) | Anti-aging cosmetic composition | |
| KR102033089B1 (en) | Compositions for decreasing sebum, skin desquamation and skin suppression | |
| CN105769666A (en) | Composition and skin care product containing same | |
| EP2260829A2 (en) | Use of an extract from snow algae in cosmetic or dermatological formulations | |
| KR20100095447A (en) | External skin preparation for pimpled skin | |
| KR101425031B1 (en) | Cosmetic composition for anti-irritation and skin moisturization containing Citrus junos Siebold seed oil and Mangifera Indica seed oil | |
| KR100435855B1 (en) | Composition for external application to the skin containing Opuntia ficus-indica extract | |
| KR102067009B1 (en) | Inhibitor for NO activator, Anit-inflammation agent containing of the same, Revitalizing cosmetics containing the same and Manufacturing method thereof | |
| US20030044449A1 (en) | Physiologically functional foods or cosmetics containing sphingoglycolipids and processes for their production | |
| CN103784365A (en) | Whitening cream and preparation method thereof | |
| KR20100067773A (en) | Cosmetic composition comprising mixture extract and preparation thereof | |
| CN111494303A (en) | Oil control composition, application of oil control composition in cosmetics and cosmetics | |
| JP2008239493A (en) | External preparation for skin | |
| CN113425661B (en) | Plant composition with cleaning and repairing effects and application thereof | |
| KR102063686B1 (en) | Skin external composition containing extract of soybean root | |
| JP2588723B2 (en) | Hair cosmetics | |
| JP6869415B2 (en) | Skin care compositions that improve skin barrier function, methods of manufacturing skin care compositions and skin care products | |
| JP2023182737A (en) | Agent for suppressing/improving bad skin caused by fatigue and/or stress and screening method for the same | |
| CN115969750B (en) | Composition for relieving and repairing as well as preparation method and application thereof | |
| JP2008239494A (en) | External preparation for skin | |
| JPH0532556A (en) | Skin agent for external use | |
| US20100158842A1 (en) | Natural skin whitener: 4-hydroxy-oxindole-3-acetic acid | |
| CN115607476A (en) | Composition with moisturizing and antioxidant effects and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |